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Dl and D2 dopamine receptors are G-protein coupled receptors and have seven transmembrane spannmg regions (TM) typical of this receptor 
superfamily. Although dopamine binds equally to Dl and D2 receptors, many compounds are highly selective. To probe the receptors for regions 
that determine subtype specificity, plasmid constructs coding for the Dl or a Dl/D2 chimeric receptor were made and transfected mto cells to study 
the bindmg and agonist properties of non-selective or subtype-selective compounds The results suggest that the DZ-selective agonist, quinpirole. 
gains much of its selectivity by bmdmg to withm TM VI and VII of the D2 receptor. 
Dl dopamme receptor; D2 dopamme receptor; Chimeric dopamme receptor 
1. INTRODUCTION 
Dopamine receptors have been classified into Dl and 
D2 subtypes [l] and this classification has been ex- 
tended to newly discovered dopamine receptors (D3, 
D4, D5) which have been categorized as either ‘D 1 -like’ 
or ‘D2-like’ [2]. The Dl-D2 classifications are largely 
based on binding affinities as well as signalling proper- 
ties of the receptors. Briefly, Dl receptors bind the ben- 
zazapine SCH 23390 with low nanomolar affinity and 
Dl agonists stimulate adenylyl cyclase whereas D2 re- 
ceptors bind the butyrophenone spiperone with pico- 
molar affinity and D2 agonists inhibit adenylyl cyclase 
[3]. In the present study, we explored the receptor basis 
of subtype-selective dopaminergic ligands by making a 
Dl/D2 receptor chimera. 
Previous studies suggested that the transducing do- 
main of G-protein coupled P,-adrenergic receptors re- 
sided in the third cytoplasmic loop [4,5]. Moreover, 
additional studies employing chimeric receptors and 
site-directed mutagenesis indicated that the ligand sub- 
type selectivity for adrenergic receptors might derive 
from sequences in TM VI and VII [5,6]. To see if these 
results would extend to another set of catecholaminer- 
gic receptors, namely dopamine receptors, we made a 
D l/D2 receptor chimera containing D 1 sequences from 
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the N-terminal through to the C-terminal end of the 
third cytoplasmic loop and D2 sequences from the be- 
ginning of TM VI to the C-terminal of the receptor. We 
predicted that the chimeric receptor would differ from 
the wild-type Dl receptor by exhibiting (1) decreased 
affinity for Dl-selective ligands, (2) increased affinity 
for a D2 ligand. and (3) activation of a Dl response by 
a D2 ligand. 
2. MATERIALS AND METHODS 
2.1. Wild-type human DI and chwneric DliD2 receptor constructs 
Standard procedures were used for DNA manipulations [7]. The 
polymerase chain reaction (PCR) was used to construct the chimeric 
Dl/D2 receptor such that the junction between Dl and D2 segments 
was the beginnmg of TM VI (Fig. 1). To obtain the segment of the 
human Dl receptor Including up to TM VI. one oligonucleotide was 
made, tatgcggccgcagagcccctgatgtgctt, that spanned the Initiator 
methionine and another oligonucleotide, tgcgctagcgtcttcaggactttag- 
tttc, was made that spanned the junction of the third cytoplasmic loop 
and TM VI of the human Dl receptor. To obtain TM VI and VII of 
the rat D2 receptor, one oligonucleotide was made that spanned the 
third cytoplasmic loop and TM VI, cctgctagccattgttctcggtgtgttca, and 
another oligonucleotide was made, atcgggcccatgaggtctggcctgcata. that 
spanned the termination codon of the rat D2 receptor. These pairs of 
oligonucleotides were used m separate PCR reactions containing plas- 
mid DNA encoding either the human Dl receptor [8] or the rat D2 
receptor [9] using a GeneAmp kit (Perkin-Elmer Cetus. Norwalk, CT) 
according to the supplier’s protocol. Rat, as opposed to human, D2 
sequences were used because we had the rat cDNA on hand and the 
amino acid sequences of these species from the beginning of TM VI 
to the C-terminal differ by only one conservative substitution (rat 
Leu-438 + human Met-438) located in the cytoplasmic tail of the 
receptor [IO]. The Dl product was cut with Not1 and NheI restriction 
enzymes and the D2 product was cut with Nhel and ApaI restriction 
enzymes. Following gel purification, the products were subcloned into 
NotI-ApaI sites of the eukaryotic expression plasmid Rc/CMV (In- 
vitrogen, San Diego, CA). The resulting plasmid was completely se- 
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quenced on both strands to be sure errors were not introduced during 
the PCR or subcloning. The wild-type human Dl receptor plasmtd has 
previously been described [1 11. All plasmtd DNAs used for transfec- 
tions were purified twice usmg cesmm chlortde gradients. 
2.2. Espremon of wild-type undmutant receptors in COS-7 and HEK- 
293 cells 
COS-7 cells (ATCC# CRLl651) were maintained and transfected 
for binding assays usmg the DEAE-dextran method as previously 
described [11] HEK-293 cells (ATCC# CRLI 573) were grown and 
mamtained m mmimal essential medium (HEPES-buffered) contain- 
mg 10% fetal bovine serum and antibiottc/antimycottc solutton HEK- 
293 cells were transfected for functional assays wtth DNA (20 pg/ 
3.5 x 10b cells) using a modified calcmm phosphate procedure [12]. 
Cells were used m either binding or functtonal assays 72 h post- 
transfection. 
2.3. Receptor bindtng assays 
Transiently transfected COS-7 cells were harvested 72 h post-trans- 
fectton and the membranes of untrdnsfected cells and cells transfected 
with the Dl or DllD2 chimeric constructs were assayed by saturatton 
bmding analysis for Dl bmdmg sites using the Dl-spectfic radtoligand 
[‘H]SCH 23390. The concentrattons of [‘HISCH 23390 ranged from 
0.1-l 2 nM for the wild-type saturation curves and from 1.25560 nM 
for the analyses of the membranes derived from the untransfected and 
Dl/D2 transfected cells. For competitton assays. membranes were 
incubated with [‘HISCH 23390 and increasing concentrations of com- 
petitor m the presence or absence of 10 PM SCH 23390 to determme 
non-specific bindmg. The concentratton of radtohgand used for wtld- 
type Dl or chtmertc Dl/D2 competitton assays was approxtmately 
equal to the KD obtamed from the saturation asaays. All bmdmg 
experiments were performed three or more ttmes. All bmdmg parame- 
ters were determmed usmg non-hnear least-squares regression analysts 
as provided by the program lnplot (GraphPad, San Dtego. CA). A 
two-sate curve was chosen for the competitton data If the residual sum 
of squares assoctated wtth the two-site fit was stgmficantly (P < 0.05) 
lower than that associated with a one-sne fit accordmg to the manual 
for Inplot (GraphPad, San Diego, CA). All other aspects of the bind- 
mg assays were as previously described [1 11. 
2.4. cAMP uccutmdut~on ussaw 
The CAMP accumulatton assays were performed as prevtously de- 
scribed [ll]. All assays were performed in triphcate The EC,,, determt- 
nattons were performed usmg the non-linear least squares regression 
analysts program of Inplot (GraphPad. San Dtego. CA). 
2.5 Compounds 
All unlabelled hgand compounds were obtamed from Research 
Btochemicals Inc. (Nattck, MA). The radtohgand. [‘H]SCH 23390 (75 
Ci/mmol). was obtained from Amersham (Arhngton Heights. IL). 
3. RESULTS AND DISCUSSION 
Saturation binding analysis of untransfected COS-7 
cells revealed a low affinity site (Kr, > 100 PM. data not 
shown) of greatly variable capacity. This site did not 
interfere with the saturation curves of the Dl or Dl/D2 
receptors since these curves modelled to single sites of 
much higher affinities. 
Transient expression in COS-7 cells was high for both 
constructs (Fig. 2). Results from saturation binding 
analyses showed that the affinity of the chimeric D 1 /D2 
receptor for the labelled Dl -selective antagonist, 
[3H]SCH 23390, was decreased nearly 20-fold relative to 
that of the wild-type Dl receptor (Fig. 2). Given the K,s 
60 
Fig. 1. (A) Amino acid sequences of the junctton site of the human Dl 
and rat D2 receptors to make the human Dl/rat D2 chimertc receptor. 
(B) Scheme of the Dl/D2 chimeric receptor. 
of the two receptors for the radioligand. we were then 
able to derive the K,s of other compounds (Table I) by 
the Cheng-Prusoff equation [ 131 after determining their 
IC,,s in competitive binding assays (Fig. 3). The data 
A Dl Saturation Curve 
6. 0102 Saturation Curve 
-0 10 20 30 40 50 60 
[3H]-SCH 23390 [nM] 
Ftg. 2. Saturatton curves using the labelled Dl receptor antagomst 
[‘H]SCH 23390 as the radiohgand. Bmdmg assays were performed on 
membranes of COS-7 cells transfected wtth constructs codmg for 
etther the human Dl receptor (A) or the human DL/rdt D2 chtmeric 
receptor (B). 
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Fig. 3. Competition curves of various dopaminergic ompounds usmg 
membranes from COS-7 cells transfected with constructs coding for 
the human Dl receptor (A) or the human DUrat D2 chimerlc receptor 
(B). The concentration of the radlolabel [‘H]SCH 23390 was approx- 
imately 0.8 nM in (A) and approximately 12 nM in (B). K, values for 
these curves appear in Table 1. 
from Table I show that, relative to the wild-type Dl 
receptor, the chimeric Dl/D2 receptor lost affinity for 
the Dl-specific compounds. SCH 23390 and SKF 38393 
and gained affinity for the D2-specific ligand, quin- 
pirole. An unexpected result was that the chimeric re- 
Results from the agonist-stimulated CAMP assays 
(Fig. 4, Table II) mirrored the pattern of results ob- 
tained in the binding experiments. Again, relative to the 
ceptor also lost affinity for the non-selective ligand, 
wild-type human Dl receptor, both the Dl- and non- 
dopamine. Indeed, the drop in affinity for dopamine 
selective compounds, SKF 38393 and dopamine, re- 
spectively, lost potency. The loss of potency by dopam- 
was greater than that for the Dl-selective agents. 
ine was greater and this was accompanied by a dimin- 
ished maximal responsiveness to dopamine (Fig. 4). In 
contrast, the potency of the D2-selective agonist, quin- 
pirole, was greatly enhanced. 
The loss of dopamine binding and potency by the 
chimeric receptor was not predicted since it is thought 
that catecholamines bind to residues contained within 
Table I 
K,s (mean f S.E.M.. PM) ofcompounds determined from competition 
curves 
Compound 
SCH 23390 
Dopamine 
SKF 38393 
Receptor 
Dl Dl/D2 
0.001 k 0.0004 0.013 + 0.001 
H 0.986 f 0.44 (67%)* H 42.8 + 5.1 (27%)* 
L 15.7 5 1.8 (33%)* L 421.6 f 21 (63%)* 
0.107 k 0.003 H 1.6 f 0.03 (79%)* 
L 64 2 ? 7.71 (21%)* 
Qulnpirole > 1.000 13.8 + 0.17 
*% of receptor population m high (H) or low (L) affinity when the 
competition curve is best fit by a two-site model as described in section 
2.3. See Fig. 3 for curves. 
The fact that the binding of the D2-selective quin- 
pirole was greatly enhanced in the chimera strongly 
points to sites in TM VI and/or VII which contribute to 
quinpirole binding. Moreover, the striking ability of this 
D2 agonist, typically associated with D2-mediated inhi- 
bition of adenylyl cyclase, to stimulate cyclase in cells 
transfected with the Dl/D2 receptor indicates that the 
D2 binding sites provided by TM VI and VII also pro- 
the first five TMs [11,14,15] and these are intact in the 
chimeric receptor. Moreover, the chimeric receptor is 
composed of two receptor subtypes, both with equal 
affinity for dopamine. Nonetheless, it is possible that 
both dopamine and the benzazapines interact with sub- 
type selective sites in TM VI and VII which prevent the 
formation of a normal binding pocket from a Dl/D2 
chimeric receptor. Unfortunately, it is also possible that 
substitution of the rat D2 sequences produced a global 
effect on the molecule to affect interactions between 
sites of the preceding Dl sequences. Therefore, in light 
of the negative impact of the chimeric receptor on 
dopamine interactions, the decreased binding of the Dl 
selective compounds for the chimera cannot be inter- 
preted as evidence for the presence of Dl selective deter- 
minants in TM VI and VII. 
Table II 
EC,,s (mean k S.E.M.. PM) determined from agomst-stimulated 
CAMP accumulation dose-response curves 
Compound Receptor 
Dl Dl/D2 
Dopamme 0.37 t 0.01 4.06 + 0.07 
SKF 38393 0.11 + 0.01 0.57 + 0.06 
Quinplrole 566.60 + 51.60 0.46 + 0.01 
See Fig. 4 for curves. 
61 
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Fig. 4. Dose-response curves of agonist-stimulated CAMP accumula- 
tion m HEK-293 ceils transfected with constructs codmg for the 
human Dl receptor or the human Dlirat D2 chimenc receptor. The 
EC,,s for these curves appear m Table II. Basal CAMP accumulation 
values (pmols/well) were: Dl-transfected cells = 3 If: 0.2 and Dl/D2- 
transfected cells = 6 t 0.6. Forskohn (lOpM)-stimulated CAMP accu- 
mulation values (pmollwell) were: Dl-transfected cells = 56 ? 8 and 
Dl/DZ-transfected cells = 79 rt 4. There was no cAMP response to 
any of the dopaminergic agonists when tested m untransfected HEK- 
293 cells. 
mote receptor activation by the agonist. Although the 
affinity of quinpirole for the chimera is greatly im- 
proved relative to the Dl receptor, it is still well below 
the affinity for the D2 receptor (typically found to be 
approximately 1 PM, [16]), suggesting that quinpirole 
might interact with other aspects of the D2 receptor 
beyond TM VI and VII. Further studies are necessary 
to determine whether all D2 selective compounds gain 
D2 selectivity by interacting at TM VI and VII determi- 
nants and also which residues within TM VI and VII 
mediate the binding of quinpirole. 
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